In conclusion, our study provides a rationale for using anti-EIF3A autoantibody as an HCC-associated biomarker and a serum ELISA using specific conformational epitope against anti-EIF3A autoantibody. The gene discussed is EIF3A; the disease is hepatocellular carcinoma.